

Ali J Olyaei

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3176664/publications.pdf>

Version: 2024-02-01

57
papers

2,936
citations

257450

24
h-index

223800

46
g-index

58
all docs

58
docs citations

58
times ranked

3377
citing authors

#	ARTICLE	IF	CITATIONS
1	The Clinical and Economic Benefit of CMV Matching in Kidney Transplant: A Decision Analysis. Transplantation, 2022, 106, 1227-1232.	1.0	7
2	The Principles of Drug Dosing in Peritoneal Dialysis. , 2021, , 349-374.		1
3	Optimal Timing of Administration of Direct-acting Antivirals for Patients With Hepatitis C-associated Hepatocellular Carcinoma Undergoing Liver Transplantation. Annals of Surgery, 2021, 274, 613-620.	4.2	3
4	Expert Consensus Statement from the American Society of Echocardiography on Hypersensitivity Reactions to Ultrasound Enhancing Agents in Patients with Allergy to Polyethylene Glycol. Journal of the American Society of Echocardiography, 2021, 34, 707-708.	2.8	25
5	Graft-versus-host disease after liver transplantation is associated with bone marrow failure, hemophagocytosis, and DNMT3A mutations. American Journal of Transplantation, 2021, 21, 3894-3906.	4.7	11
6	New onset diabetes after kidney transplantation in Asian Americans – Is there an increased risk?. Transplantation Reports, 2021, 6, 100080.	0.4	1
7	Cytomegalovirus serologic matching in deceased donor kidney allocation optimizes high- and low-risk (D+R+ and D+R-) profiles and does not adversely affect transplant rates. American Journal of Transplantation, 2020, 20, 3502-3508.	4.7	12
8	De novo thrombotic microangiopathy in two kidney transplant recipients from the same deceased donor: A case series. Clinical Transplantation, 2020, 34, e13885.	1.6	6
9	Lipid-lowering agents for the treatment of hyperlipidemia in patients with chronic kidney disease and end-stage renal disease on dialysis: a review. Drugs and Therapy Perspectives, 2019, 35, 431-441.	0.6	3
10	Sulfonamide desensitization in solid organ transplant recipients: A protocol-driven approach during the index transplant hospitalization. Transplant Infectious Disease, 2019, 21, e13191.	1.7	7
11	Biologic targeted therapy in allergic asthma. Journal of Precision Respiratory Medicine, 2019, 2, 24-34.	0.1	0
12	The efficacy and safety of direct oral anticoagulants in patients with chronic renal insufficiency: A review of the literature. European Journal of Haematology, 2019, 102, 312-318.	2.2	53
13	Outcomes of Kidney Transplantation with a CMV Matching Allocation Schema. Open Forum Infectious Diseases, 2017, 4, S11-S12.	0.9	1
14	Adherence Rates Between Once and Twice Daily Direct Oral Anticoagulants - Results of a Single University Pharmacy Cohort Study. Blood, 2016, 128, 5024-5024.	1.4	0
15	Drug Dosing in Patients with Chronic Kidney Disease and Dermatological Diseases. , 2015, , 221-253.		0
16	Tacrolimus exposure in the real world: an analysis from the <scp>M</scp>ycophenolic acid <scp>O</scp>bservational <scp>RE</scp>nal transplant study. Clinical Transplantation, 2014, 28, 768-775.	1.6	7
17	Pharmacokinetics of Lipid-Lowering Medications in Chronic Kidney Disease. , 2014, , 129-152.		0
18	Drug Dosing in Elderly Patients with Chronic Kidney Disease. Clinics in Geriatric Medicine, 2013, 29, 657-705.	2.6	17

#	ARTICLE	IF	CITATIONS
19	HMG-CoA Reductase Inhibitors in Chronic Kidney Disease. American Journal of Cardiovascular Drugs, 2013, 13, 385-398.	2.2	4
20	The Old and New Methods of Assessing Kidney Function. Journal of Clinical Pharmacology, 2012, 52, 63S-71S.	2.0	16
21	Drug dosing in patients with chronic kidney disease. , 2012, , 197-206.		0
22	Evaluation of Potential Interactions between Mycophenolic Acid Derivatives and Proton Pump Inhibitors. Annals of Pharmacotherapy, 2012, 46, 1054-1064.	1.9	17
23	Three strikes and statins out: A case against use of statins in dialysis patients for primary prevention. Dialysis and Transplantation, 2011, 40, 148-151.	0.2	0
24	A Quantitative Approach to Drug Dosing in Chronic Kidney Disease. Blood Purification, 2011, 31, 138-145.	1.8	35
25	The Efficacy and Safety of the 3-Hydroxy-3-methylglutaryl-CoA Reductase Inhibitors in Chronic Kidney Disease, Dialysis, and Transplant Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 664-678.	4.5	25
26	Topics in Transplantation Medicine for General Nephrologists. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 1518-1529.	4.5	0
27	Epidemiology and Outcomes of Candidemia in 2019 Patients: Data from the Prospective Antifungal Therapy Alliance Registry. Clinical Infectious Diseases, 2009, 48, 1695-1703.	5.8	809
28	Drug Dosing in the Elderly Patients with Chronic Kidney Disease. Clinics in Geriatric Medicine, 2009, 25, 459-527.	2.6	43
29	Presentation of the PATH Alliance® registry for prospective data collection and analysis of the epidemiology, therapy, and outcomes of invasive fungal infections. Diagnostic Microbiology and Infectious Disease, 2007, 59, 407-414.	1.8	81
30	Primer on Kidney Diseases. Annals of Internal Medicine, 2006, 144, 784.	3.9	0
31	Autosomal-dominant polycystic kidney disease as a risk factor for diabetes mellitus following renal transplantation. Kidney International, 2005, 67, 714-720.	5.2	75
32	Cardiovascular complications of immunosuppressive agents in renal transplant recipients. Expert Opinion on Drug Safety, 2005, 4, 29-44.	2.4	8
33	Hepatitis C infection increases the risk of new-onset diabetes after transplantation in liver allograft recipients. American Journal of Surgery, 2005, 189, 552-557.	1.8	40
34	Comparative Analysis of Outcome Following Liver Transplantation in US Veterans. American Journal of Transplantation, 2004, 4, 788-795.	4.7	19
35	Management of invasive aspergillosis in high-risk patients. Managed Care Interface, 2004, Suppl B, 7-21; quiz 22-3.	0.2	0
36	Graft Failure From Severe Recurrent Primary Sclerosing Cholangitis Following Orthotopic Liver Transplantation. Journal of Clinical Gastroenterology, 2003, 37, 344-347.	2.2	14

#	ARTICLE	IF	CITATIONS
37	Multicenter Evaluation of Risk Factors for Aspergillosis in Patients Treated with Lipid Amphotericin B Products: Outcomes, Drug Utilization Parameters, and Benchmarking. Hospital Pharmacy, 2003, 38, 232-240.	1.0	1
38	Immunosuppression impact on long-term cardiovascular complications after liver transplantation. American Journal of Surgery, 2002, 183, 595-599.	1.8	110
39	Late mortality after orthotopic liver transplantation. American Journal of Surgery, 2001, 181, 475-479.	1.8	108
40	Nephrotoxicity of immunosuppressive drugs: new insight and preventive strategies. Current Opinion in Critical Care, 2001, 7, 384-389.	3.2	257
41	Use of basiliximab and daclizumab in kidney transplantation. Progress in Transplantation, 2001, 11, 33-39.	0.7	13
42	RITUXIMAB IS SAFE AND EFFECTIVE FOR THE TREATMENT OF POST TRANSPLANT LYMPHOPROLIFERATIVE DISEASE.. Transplantation, 2000, 69, S321.	1.0	0
43	Renal toxicity of protease inhibitors. Current Opinion in Nephrology and Hypertension, 2000, 9, 473-476.	2.0	31
44	Effect of grapefruit juice on cyclosporin A pharmacokinetics in pediatric renal transplant patients. Pediatric Transplantation, 2000, 4, 313-321.	1.0	28
45	Association of fungal infection and increased mortality in liver transplant recipients. American Journal of Surgery, 2000, 179, 426-430.	1.8	85
46	Nephrotoxicity of immunosuppressive drugs: Long-term consequences and challenges for the future. American Journal of Kidney Diseases, 2000, 35, 333-346.	1.9	378
47	Fatal Fulminant Hepatitis Associated with Bromfenac Use. Annals of Pharmacotherapy, 1999, 33, 945-947.	1.9	39
48	Immunosuppressant-Induced Nephropathy. Drug Safety, 1999, 21, 471-488.	3.2	96
49	A Practical Guide to the Management of Hypertension in Renal Transplant Recipients. Drugs, 1999, 58, 1011-1027.	10.9	57
50	Distant processing of pancreas islets for autotransplantation following total pancreatectomy. American Journal of Surgery, 1999, 177, 423-427.	1.8	65
51	Vancomycin-resistant Enterococcus in liver transplant patients. American Journal of Surgery, 1999, 177, 418-422.	1.8	64
52	Hepatic allograft abscess with hepatic arterial thrombosis. American Journal of Surgery, 1998, 175, 354-359.	1.8	47
53	LIVER TRANSPLANTATION FOR DISULFIRAM-INDUCED HEPATIC FAILURE. American Journal of Gastroenterology, 1998, 93, 830-831.	0.4	21
54	EFFICACY AND SAFETY OF LOW MOLECULAR WEIGHT HEPARIN IN RENAL TRANSPLANTATION1. Transplantation, 1998, 66, 533-534.	1.0	41

#	ARTICLE	IF	CITATIONS
55	Switching Between Cyclosporin Formulations What are the Risks?. Drug Safety, 1997, 16, 366-373.	3.2	27
56	DEVELOPMENT OF GANCICLOVIR RESISTANCE DURING TREATMENT OF PRIMARY CYTOMEGALOVIRUS INFECTION AFTER LIVER TRANSPLANTATION1. Transplantation, 1997, 63, 476-478.	1.0	65
57	Pharmacology of immunosuppressive medications used in renal diseases and transplantation. American Journal of Kidney Diseases, 1996, 28, 631-667.	1.9	63